microcatheterWe are reporting the successful treatment of a patient with a heterozygous factor V Leiden mutation who presented with spontaneous thrombotic ischemia of ring and small fingers. Microcatheter-directed administration of thrombolytics at the level of common and proper digital arteries resulted ...
Factor V Leiden refers to the c.1691G>A variant in the FV gene, which encodes coagulation factor V. This variant results in resistance to factor V protein degradation by activated protein C and increases the risk of VTE 6 to 8 fold in heterozygous carriers and 80 fold in homozygous carrier...
Bovill EG, Bauer KA, Dickermann JD, Callas P, West B (1989) The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood 73: 712–717 PubMed CAS Google Scholar Budowle B, Chakraborty R, Giusti AM, Eisenberg A J, Allen R C (1991) Analysis of the...
In a re- cent study of thrombophilic families, individuals homozygous for Factor V Leiden or doubly heterozygous for Factor V Leiden and the prothrombin 20210GϾA mutations did not have an increased risk for recurrence, even when the analysis was restricted to those with a first idiopathic VTE...
Activated protein C resistance, caused by a point mutation factor V gene was described in last decade. This article highlights a case of a 9 year-old-boy who admitted to Baskent University Hospital with right- sided hemiplegia. He was diagnosed as heterozygous for the FVL mutation and with ...
It is well documented that factor V Leiden mutation (FVL) is a common hypercoagulable risk factor in the Caucasian population. Patients with homozygous FVL mutation have an increased risk for venous thromboembolism. However, there have been few cases of heterozygous FVL mutation associated with ...
Presents a letter to the editor regarding a Budd-Chiari syndrome with underlying homozygous factor V Leiden and heterozygous methylenetetrahydrofolate reductase mutations.doi:10.1007/s00535-005-1664-2Kassem A. BaradaCecilio R. AzarZaher K. Otrock...
Mycophenolate mofetil causing deep venous thrombosis in a renal transplant patient with factor V Leiden Mycophenolate mofetil (MMF) is a drug that is commonly used as a post‐transplant immunosuppressive agent. The mechanism of action of MMF is via non‐compe......
14 The stroke risk associated with the heterozygous mutation was increased 3.8-fold, either mutation was increased 5.5-fold, and the homozygous mutation was increased 208-fold. From a clinical perspective more studies are needed to clarify the role of this mutation in stroke from either a ...
Coagulation Studies, Factor V Leiden, and Anticardiolipin Antibodies in 40 Cases of Cerebral Venous Thrombosis (15%) were found: 1 protein C deficiency, 1 protein S deficiency, and 4 activated protein C resistance with heterozygous factor V Leiden mutation (10%... Deschiens,M.-A.,Conard,.....